MDRNAMeroduplex Ribonucleic Acid
References in periodicals archive ?
Houston was previously Vice President of Chemistry and Formulations at MDRNA, Inc.
is acting as financial advisor and Pryor Cashman LLP as legal advisor to MDRNA on this transaction.
Brandt served as Executive Vice President, Clinical Research and Medical Affairs at MDRNA, Inc.
He has also served at Ascent Therapeutics as Vice President, Preclinical Chemistry and CMC; at MDRNA, Inc.
License from MDRNA (now Marina Biotech) providing access to Meroduplex siRNA structures;
Hibben served as Chief Business Officer of Cequent Pharmaceuticals, a company developing therapeutics based on RNAi, where he played a key role in Cequent's $46 million merger with MDRNA, Inc.